.jpeg)
2026-05-11 02:36:52
Pralsetinib, a highly selective RET inhibitor, is revolutionizing treatment for RET fusion-positive NSCLC and MTC. This article delves into its mechanism, clinical data, administration guidelines, and global accessibility, offering essential insights for patients and clinicians.
2026-05-06 03:26:04
Benralizumab (Fasenra) is generally safe for severe eosinophilic asthma, but potential risks exist. This guide covers common side effects (headache, sore throat), hypersensitivity, infection risks, and rare severe reactions, providing actionable strategies for patients and clinicians.
2026-05-06 03:15:20
Lemborexant, a novel insomnia medication, targets the orexin system to regulate sleep-wake cycles. Clinically proven to improve sleep onset and maintenance, it offers lower residual effects and dependency risks than traditional drugs, providing a safer alternative for adult insomnia patients.
2026-04-30 04:30:10
This article details the latest progress of AstraZeneca's Breztri Aerosphere, which received US FDA approval on April 28, 2026, for the maintenance treatment of asthma in patients aged 12 years and older. It analyzes its mechanism of action as the world's first single-inhaler triple therapy, key Phase III KALOS and LOGOS trial data, clinical value, and global regulatory status.
2026-04-30 04:24:41
This article provides a comprehensive interpretation of the core data from the international Phase III TROPION-Breast02 trial, comparing the efficacy, safety, and patient-reported outcomes of datopotamab deruxtecan versus chemotherapy as first-line treatment for advanced triple-negative breast cancer ineligible for immunotherapy, and discussing its clinical positioning, study limitations, and impact on the treatment landscape.
2026-04-30 04:14:23
This article details the mechanism of action, precise indications, eligible patient populations, and clinical value of elacestrant, analyzing its unique advantages and application boundaries in the treatment of endocrine-resistant hormone receptor-positive breast cancer.
2026-04-30 04:02:14
This article comprehensively reviews the latest research progress of vibegron in 2026, covering its core efficacy verification in overactive bladder (OAB), long-term safety evaluation, and expanded application in male patients with concomitant benign prostatic hyperplasia, analyzing key clinical trial data and clinical value.
2026-04-30 03:21:05
This article provides a detailed overview of elafibranor's mechanism of action in cholestatic liver diseases such as primary biliary cholangitis (PBC), analyzes its efficacy maintenance characteristics during long-term treatment, clarifies the applicable boundaries of the "drug resistance" concept, and explains key clinical monitoring points.
2026-04-30 03:16:38
This article provides a detailed overview of benzgalantamine (brand name Zunveyl) in the treatment of Alzheimer's disease, including its mechanism of action, optimal efficacy periods, clinical manifestations, and target patient populations, clarifying its core value and limitations as a symptomatic treatment medication.
2026-04-29 06:37:21
Loargys(Pegzilarginase-nbln) is a pegylated arginase replacement therapy for the long-term management of arginase 1 deficiency. This guide provides detailed information on pre-treatment preparation, dose adjustment and monitoring requirements during treatment, and standardized home subcutaneous injection procedures to help patients and healthcare providers use this medication safely and effectively.
2026-04-29 06:05:15
Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte colony-stimulating factor (G-CSF) for hematopoietic stem cell collection and autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma. This article provides detailed information on various side effects of plerixafor, including serious adverse reactions requiring immediate medical attention, common mild to moderate reactions, and systematic side effect management protocols for healthcare professionals.
2026-04-29 05:05:24
Selpercatinib is a highly selective RET kinase inhibitor indicated for the treatment of multiple advanced solid tumors associated with RET gene alterations, including non-small cell lung cancer, medullary thyroid cancer, and RET fusion-positive thyroid cancer. This guide provides detailed information on its indications, recommended dosage, dosage adjustments for special populations, important safety warnings, and drug interactions.
